The new, negative 2.5% efficiency adjustment will be applied to the vast majority of Medicare payments for physician services. It was opposed by cardiology and most other medical societies. 

Electrophysiologists can now perform cardiac ablation outside of a hospital setting. Groups such as the American College of Cardiology and Heart Rhythm Society have been pushing for this change for quite some time, pointing to the potential to cut costs and boost patient satisfaction.

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. 

SCAI President Srihari Naidu, MD, detailed some of the challenges interventional cardiologists face as reimbursements keep declining. The group has been building new partnerships with other medical societies to strengthen its influence in Washington. 

The company, founded in 1966, has been providing supplies to cardiac surgery suites and cath labs for decades.

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.

With no treatments available that directly improve INOCA, this breakthrough device offers hope.

Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.